Type 2 immune profile and impaired SMAD3-mediated repair in refractory stasis dermatitis responsive to IL-4Rα blockade

Published: 6 April 2026| Version 1 | DOI: 10.17632/hgr545cz2f.1
Contributor:
Chen Shen

Description

Supplementary Table 1. Additional information of baseline characteristics of patients with stasis dermatitis treated with dupilumab

Files

Categories

Immunology, Clinical Research

Related Links

Article
https://mail.qq.com/cgi-bin/frame_html?sid=kV3hNIv9nWe0Ihd_&r=b1d6df44a51b0cecef01a7ab03428ef6&lang=zh
is related to this dataset

Licence